Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (82791)	2/14/2000 3:24:00 AM
From: Jenna	Read Replies (1) \| Respond to of 120523

CEGE..HYSQ from a previous watch lists (CELG which I thought I was stuck with, moved up nicely) could be its turn to move up sharply. GENXY, CRXA, GENE, CBST, ABSC, GLGC, all exploded to the upside. Cell Genesis for example is losing less and less money every quarter. They are one of the few biotechs that are a cash cow and has about $500 million. So even if their drugs don't come to market until 2003, they are 'well-padded' against any unusual downturns in the gene therapy group. CEGE has actually earned $0.10 cents this yar versus a loss of $0.23 last year. Revenue is up 144%.. HYSQ the next choice in the gene arene.. HYSQ has 2 product candidates at the preclinical stage awaiting FDA testing approval. Its important to have 1 or 2 of these stock long term since it should only take a few years to compile the whole genetic code of man's genes. HYSQ has the largest collection of human genes in the world.. and owns the most advanced technology for sequencing and analyzing the human blueprints that make up these genes. HYSQ ranks #1 in identifying rare genes that are important for the pharmaceutical companies. And like CEGE, HYSQ also knows how to make money. They are licensing their genes to other companies and getting into contracts (the most recent was $60 million) for yet further research, this time on animal genes. The revenue on these huge contracts will keep HYSQ in revenues until their products are approved.